Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Asahi Kasei Corp    3407   JP3111200006

News SummaryMost relevantAll newsSector newsTweets

Asahi Kasei Corp. : Construction of new acetonitrile plant in Korea

share with twitter share with LinkedIn share with facebook
share via e-mail
03/06/2012 | 04:35am CEST

Asahi Kasei Chemicals Corp.

Asahi Kasei Chemicals has finalized a decision to construct a new acetonitrile plant in Korea. The plant will have a production capacity of 11,000 tons per year, and start-up is scheduled for January 2014. Having a second production base for acetonitrile, in addition to its Japanese base, will enable Asahi Kasei Chemicals to assure a reliable supply of acetonitrile as demand continues to grow rapidly worldwide.

Acetonitrile is produced by refining the crude acetonitrile obtained as a byproduct of acrylonitrile (AN). It is mainly used as a solvent in the manufacture of pharmaceuticals, with other notable uses including as analytical reagent and in the field of agrichemicals. With an acetonitrile plant in Kawasaki, Kanagawa, Japan, having a production capacity of 14,000 tons per year, Asahi Kasei Chemicals is a major supplier to markets in Asia and Europe as well as Japan. Strong growth in demand for acetonitrile is forecasted, particularly for use in the field of pharmaceutical manufacture. Asahi Kasei Chemicals had therefore been examining how best to increase production capacity and ensure reliable supply as markets continue to grow.

A decision was made to construct a new acetonitrile plant at Tong Suh Petrochemical Corp., Ltd., an Asahi Kasei Group company in Korea, which is currently constructing a new AN plant in Ulsan with startup scheduled for January 2013. The acetonitrile plant in Korea will utilize crude acetonitrile byproduct from the AN plants in Korea.

Having two production bases for acetonitrile, in Japan and Korea, will enable Asahi Kasei Chemicals to provide reliable supply to meet growing demand in the pharmaceutical industry especially in India and China.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASAHI KASEI CORP
07/24 ASAHI KASEI : to increase production capacity for SBR in Singapore
07/15 ASAHI KASEI : U.S. Patents Awarded to Inventors in Colorado (July 15)
07/11 ASAHI KASEI : Home Order Trends – June 2017
07/07 ASAHI KASEI : Global Hemofiltration Machines Market 2017 - Baxter Healthcare Cor..
06/29 HAEMONETICS : Global Blood Filter Market 2017 - Asahi Kasei Medical, Chengdu Shu..
06/29 ASAHI KASEI : Investigators at Asahi Kasei Pharma Corporation Release New Data o..
06/26 ASAHI KASEI : NIMS and Four Chemical Companies to Develop a Framework for Promot..
06/24 COLLEGIUM PHARMACEUTICAL : U.S. Patents Awarded to Inventors in Pennsylvania (Ju..
06/22 ASAHI KASEI : Researchers from Asahi Kasei Pharma Corporation Describe Findings ..
06/22 ASAHI KASEI : "Current Sensor" in Patent Application Approval Process (USPTO 201..
More news
News from SeekingAlpha
01/19 Evotec collaborates with Japan's Asahi Kasei Pharma on drug discovery
2016 JAPANESE EQUITIES : False Dawn Or Rising Star?
2016 GMO International Active EAFE Strategy Q3 2016 Commentary
2016 A YEAR OF SCANDAL : The Beginning Of The End Of Cronyism In Japan?
2016 Array Bio licenses TrkA inhibitors to Asahi Kasei Pharma in Asia for up to $7..
Financials ( JPY)
Sales 2018 1 971 850 M
EBIT 2018 -
Net income 2018 117 711 M
Debt 2018 181 738 M
Yield 2018 1,89%
P/E ratio 2018 15,47
P/E ratio 2019 14,61
EV / Sales 2018 1,01x
EV / Sales 2019 0,94x
Capitalization 1 808 674 M
Duration : Period :
Asahi Kasei Corp Technical Analysis Chart | 3407 | JP3111200006 | 4-Traders
Technical analysis trends ASAHI KASEI CORP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Average target price 1 190  JPY
Spread / Average Target -7,7%
EPS Revisions
Hideki Kobori President & Representative Director
Ichiro Itoh Chairman
Norio Ichino Independent Director
Masafumi Nakao Director
Yuji Kobayashi Representative Director
Sector and Competitors
1st jan.Capitalization (M$)
ASAHI KASEI CORP23.64%16 283
AIR LIQUIDE0.71%48 144
PRAXAIR, INC.15.39%38 586